Repro Med Systems Stock Today
| KRMD Stock | USD 2.68 0.01 0.37% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Repro Med is trading at 2.68 as of the 25th of September 2024, a 0.37 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.67. Repro Med has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Repro Med Systems are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of October 2022 and ending today, the 25th of September 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 20th of March 1996 | Category Healthcare | Classification Health Care |
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York. The company has 45.86 M outstanding shares of which 215.86 K shares are now shorted by private and institutional investors with about 4.04 trading days to cover. More on Repro Med Systems
Moving against Repro Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Repro Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Linda Tharby | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRepro Med can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Repro Med's financial leverage. It provides some insight into what part of Repro Med's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repro Med Systems (KRMD) is traded on NASDAQ Exchange in USA. It is located in 100 Corporate Drive, Mahwah, NJ, United States, 07430 and employs 82 people. Repro Med is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 122.89 M. Repro Med Systems conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 45.86 M outstanding shares of which 215.86 K shares are now shorted by private and institutional investors with about 4.04 trading days to cover.
Repro Med Systems currently holds about 18.27 M in cash with (4.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Check Repro Med Probability Of Bankruptcy
Ownership AllocationRepro Med owns a total of 45.86 Million outstanding shares. Over half of Repro Med's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Repro Ownership Details
Repro Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-06-30 | 260.6 K | |
| Blackrock Inc | 2024-06-30 | 186.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 168.2 K | |
| State Street Corp | 2024-06-30 | 126.7 K | |
| Alpine Partners Vi, Llc | 2024-06-30 | 107.2 K | |
| Washington Trust Co | 2024-06-30 | 100 K | |
| Pnc Financial Services Group Inc | 2024-06-30 | 97 K | |
| Jane Street Group, Llc | 2024-06-30 | 93.9 K | |
| Citadel Advisors Llc | 2024-06-30 | 92.5 K | |
| First Light Asset Management, Llc | 2024-06-30 | 5 M | |
| Vanguard Group Inc | 2024-06-30 | 1.8 M |
Repro Med Historical Income Statement
Repro Stock Against Markets
Repro Med Corporate Management
| Brian Case | Chief Officer | Profile | |
| Thomas Adams | Chief Officer | Profile | |
| Rob Cannon | Vice Sales | Profile | |
| Josh Bennett | VP Devel | Profile | |
| Kenneth Miller | Chief Officer | Profile | |
| Tom Adams | Interim Officer | Profile |
Additional Information and Resources on Investing in Repro Stock
When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.25) | Revenue Per Share 0.674 | Quarterly Revenue Growth 0.215 | Return On Assets (0.14) |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.